XML 30 R5.htm IDEA: XBRL DOCUMENT v3.22.0.1
Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) - USD ($)
$ in Thousands
Total
Redeemable Convertible Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2019   635,048        
Beginning balance at Dec. 31, 2019   $ 73,568        
Redeemable Convertible Preferred Stock            
Issuance of Series B’ redeemable convertible preferred stock (in shares)   7,599,720        
Issuance of Series B’ redeemable convertible preferred stock, net of issuance costs of $1,304   $ 31,696        
Conversion of convertible notes into Series B' redeemable convertible preferred stock (in shares)   8,379,410        
Conversion of convertible notes into Series B' redeemable convertible preferred stock $ 4,148 $ 36,386   $ 4,148    
Reduction of Series A' redeemable convertible preferred stock liquidation value $ 228 $ (228)       $ 228
Ending balance (in shares) at Dec. 31, 2020 16,614,178 16,614,178        
Ending balance at Dec. 31, 2020 $ 141,422 $ 141,422        
Beginning balance (in shares) at Dec. 31, 2019     202,121      
Beginning balance at Dec. 31, 2019 (129,350)   $ 0 234,290 $ 1 (363,641)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss (24,278)         (24,278)
Unrealized gain (loss) on available-for-sale debt securities $ 32       32  
Issuance of common stock pursuant to stock option exercises (in shares) 112,049   112,049      
Issuance of common stock pursuant to stock option exercises $ 11     11    
Conversion of convertible notes into Series B' redeemable convertible preferred stock (in shares)   8,379,410        
Conversion of convertible notes into Series B' redeemable convertible preferred stock 4,148 $ 36,386   4,148    
Reduction of Series A' redeemable convertible preferred stock liquidation value 228 $ (228)       228
Repurchase of common stock (in shares)     (74)      
Change in early exercise liability (2)     (2)    
Stock-based compensation $ 1,379     1,379    
Ending balance (in shares) at Dec. 31, 2020 314,096   314,096      
Ending balance at Dec. 31, 2020 $ (147,832)   $ 0 239,826 33 (387,691)
Redeemable Convertible Preferred Stock            
Net exercise of Series B’ redeemable convertible preferred stock warrants (in shares)   213,941        
Net exercise of Series B’ redeemable convertible preferred stock warrants   $ 5,606        
Ending balance (in shares) at Dec. 31, 2021 0 0        
Ending balance at Dec. 31, 2021 $ 0 $ 0        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss (36,080)         (36,080)
Unrealized gain (loss) on available-for-sale debt securities $ (305)       (305)  
Issuance of common stock pursuant to stock option exercises (in shares) 300,768   300,768      
Issuance of common stock pursuant to stock option exercises $ 8   $ 0 8    
Change in early exercise liability       (2)    
Conversion Of Redeemable Convertible Preferred Stock Into Common Stock Shares   (16,828,119) (16,828,119)      
Conversion of redeemable convertible preferred stock into common stock (147,028) $ (147,028) $ (17) (147,011)    
Net exercise of common stock warrants (in shares)     185      
Issuance of common stock upon initial public offering, net of issuance costs and underwriting discount of $11,813 (in shares)     6,900,000      
Issuance of common stock upon initial public offering, net of issuance costs and underwriting discount of $11,813 105,487   $ 7 105,480    
Issuance of common stock pursuant to Employee Stock Purchase Plan 911     911    
Issuance of shares pursuant to Employee Stock Purchase Plan (in shares)     109,831      
Change in early exercise liability (2)          
Stock-based compensation $ 4,288     4,288    
Ending balance (in shares) at Dec. 31, 2021 24,452,999   24,452,999      
Ending balance at Dec. 31, 2021 $ 73,503   $ 24 $ 497,522 $ (272) $ (423,771)